肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床进展

doi:10.35541/cjd.20210420

中华皮肤科杂志 ›› 2022, e20210420.doi: 10.35541/cjd.20210420

肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床进展

陆佳维鲁严

南京医科大学第一附属医院江苏省人民医院皮肤科，南京 210029

收稿日期:2021-06-01 修回日期:2021-09-09 发布日期:2022-02-08
通讯作者: 鲁严 E-mail:luyan6289@163.com
基金资助:
国家自然科学基金（81872541）

Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents

Lu Jiawei, Lu Yan

Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Received:2021-06-01 Revised:2021-09-09 Published:2022-02-08
Contact: Lu Yan E-mail:luyan6289@163.com
Supported by:
National Natural Science Foundation of China（81872541）

摘要/Abstract

摘要： 【摘要】肿瘤坏死因子α（TNF-α）抑制剂（TNFi）已成为慢性炎症性疾病患者无法耐受传统治疗或传统治疗失败时的重要选择。2% ~ 5%使用TNFi的患者会诱发银屑病皮损或加重银屑病，TNFi既是治疗银屑病的药物又是诱因时，被称为矛盾性银屑病。矛盾性银屑病与经典银屑病的临床表现类似，但免疫学机制不同。该文概述了矛盾性银屑病的发病机制、临床病理特点和处置流程，同时总结了其他常见生物制剂使用中出现矛盾性银屑病的概况。

关键词: 银屑病, 肿瘤坏死因子α, 生物制剂, 药物毒性, 矛盾性银屑病

Abstract: 【Abstract】 Tumor necrosis factor（TNF）-α inhibitors have become an important choice for patients with chronic inflammatory diseases who were intolerant or poorly responsive to conventional therapies. Studies have shown that psoriasis can develop or be exacerbated in 2% - 5% of patients treated with TNF-α inhibitors, and this phenomenon is called paradoxical psoriasis. Paradoxical psoriasis and classic psoriasis have similar clinical manifestations, but different immunological mechanisms. This review summarizes the pathogenesis, clinicopathological features and management of paradoxical psoriasis, and provides an overview of paradoxical psoriasis following the application of other common biological agents.

Key words: Psoriasis, Tumor necrosis factor-alpha, Biological agents, Drug toxicity, Paradoxical psoriasis

陆佳维, 鲁严. 肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床进展[J]. 中华皮肤科杂志, 2022,e20210420. doi:10.35541/cjd.20210420

Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents[J]. Chinese Journal of Dermatology,2022,e20210420. doi:10.35541/cjd.20210420

参考文献 40

［1］	Bucalo A, Rega F, Zangrilli A, et al. Paradoxical psoriasis induced by anti⁃TNFα treatment: evaluation of disease⁃specific clinical and genetic markers［J］. Int J Mol Sci, 2020,21（21）:7873. doi: 10.3390/ijms21217873.
［2］	Cabaleiro T, Prieto⁃Pérez R, Navarro R, et al. Paradoxical psoriasiform reactions to anti⁃TNFα drugs are associated with genetic polymorphisms in patients with psoriasis［J］. Pharmacogenomics J, 2016,16（4）:336⁃340. doi: 10.1038/tpj. 2015.53.
［3］	Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis［J］. Nat Commun, 2018,9（1）:25. doi: 10.1038/s41467⁃017⁃02466⁃4.
［4］	Fania L, Morelli M, Scarponi C, et al. Paradoxical psoriasis induced by TNF⁃α blockade shows immunological features typical of the early phase of psoriasis development［J］. J Pathol Clin Res, 2020,6（1）:55⁃68. doi: 10.1002/cjp2.147.
［5］	Aerts NE, De Knop KJ, Leysen J, et al. Increased IL⁃17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration⁃associated chemokine receptor expression［J］. Rheumatology （Oxford）, 2010,49（12）:2264⁃2272. doi: 10. 1093/rheumatology/keq224.
［6］	Talotta R, Berzi A, Atzeni F, et al. Paradoxical expansion of Th1 and Th17 lymphocytes in rheumatoid arthritis following infliximab treatment: a possible explanation for a lack of clinical response［J］. J Clin Immunol, 2015,35（6）:550⁃557. doi: 10. 1007/s10875⁃015⁃0182⁃0.
［7］	Zou J, Rudwaleit M, Brandt J, et al. Down⁃regulation of the nonspecific and antigen⁃specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab［J］. Arthritis Rheum, 2003,48（3）:780⁃790. doi: 10.1002/art.10847.
［8］	Moran B, Gallagher C, Tobin AM, et al. Enrichment of polyfunctional IL⁃17⁃producing T cells in paradoxical psoriasis skin lesions［J］. J Invest Dermatol, 2020,140（5）:1094⁃1097. doi: 10.1016/j.jid.2019.10.010.
［9］	Cohen JN, Bowman S, Laszik ZG, et al. Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: a retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β⁃defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor⁃associated dermatitis［J］. J Am Acad Dermatol, 2020,82（2）:430⁃439. doi: 10.1016/j.jaad.2019.08.023.
［10］	Tillack C, Ehmann LM, Friedrich M, et al. Anti⁃TNF antibody⁃induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon⁃γ⁃expressing Th1 cells and IL⁃17A/IL⁃22⁃expressing Th17 cells and respond to anti⁃IL⁃12/IL⁃23 antibody treatment［J］. Gut, 2014,63（4）:567⁃577. doi: 10.1136/gutjnl⁃2012⁃302853.
［11］	Xueyi L, Lina C, Zhenbiao W, et al. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti⁃TNF⁃α therapy［J］. J Clin Immunol, 2013,33（1）:151⁃161. doi: 10.1007/s10875⁃012⁃9774⁃0.
［12］	Moy AP, Murali M, Kroshinsky D, et al. T⁃helper immune phenotype may underlie ′paradoxical′ tumour necrosis factor⁃α inhibitor therapy⁃related psoriasiform dermatitis［J］. Clin Exp Dermatol, 2018,43（1）:19⁃26. doi: 10.1111/ced.13227.
［13］	Nguyen DX, Ehrenstein MR. Anti⁃TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF⁃TNF⁃RII binding in rheumatoid arthritis［J］. J Exp Med, 2016,213（7）:1241⁃1253. doi: 10.1084/jem.20151255.
［14］	Odai T, Matsunawa M, Takahashi R, et al. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis［J］. J Rheumatol, 2009,36（6）:1158⁃1165. doi: 10.3899/jrheum.081074.
［15］	Greisen SR, Schelde KK, Rasmussen TK, et al. CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic ′window of opportunity′［J］. Arthritis Res Ther, 2014,16（5）:434. doi: 10.1186/s13075⁃014⁃0434⁃z.
［16］	van Lieshout AW, Fransen J, Flendrie M, et al. Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis［J］. Ann Rheum Dis, 2007,66（10）:1334⁃1338. doi: 10.1136/ard.2006.06 6084.
［17］	Han BK, Kuzin I, Gaughan JP, et al. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study［J］. Arthritis Res Ther, 2016,18:93. doi: 10.1186/s13075⁃016⁃0995⁃0.
［18］	Goldminz AM, Suárez⁃Fariñas M, Wang AC, et al. CCL20 and IL22 messenger RNA expression after adalimumab vs methotrexate treatment of psoriasis: a randomized clinical trial［J］. JAMA Dermatol, 2015,151（8）:837⁃846. doi: 10.1001/jamadermatol.2015.0452.
［19］	Khanniche A, Zhou L, Jiang B, et al. Restored and enhanced memory T cell immunity in rheumatoid arthritis after TNFα blocker treatment［J］. Front Immunol, 2019,10:887. doi: 10.3389/ fimmu.2019.00887.
［20］	Murphy MJ, Cohen JM, Vesely MD, et al. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis［J/OL］. J Am Acad Dermatol, 2020:S0190⁃9622（20）33154⁃6［2021⁃06⁃01］. https://www.sciencedirect.com/science/article/pii/S0190962220331546?via%3Dihub. doi: 10.1016/j.jaad.2020.12.010.
［21］	Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL⁃17 treatment: a case series and review of the literature［J］. Expert Opin Biol Ther, 2020,20（6）:665⁃672. doi: 10.1080/14712598.2020.1727439.
［22］	Stoffel E, Maier H, Riedl E, et al. Analysis of anti⁃tumour necrosis factor⁃induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics［J］. Br J Dermatol, 2018,178（5）:1151⁃1162. doi: 10.1111/bjd.16126.
［23］	Ishiuji Y, Umezawa Y, Asahina A, et al. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases［J］. J Dermatol, 2018,45（6）:732⁃734. doi: 10.1111/1346⁃8138. 14295.
［24］	Hu JZ, Billings SD, Yan D, et al. Histologic comparison of tumor necrosis factor⁃α inhibitor⁃induced psoriasis and psoriasis vulgaris［J］. J Am Acad Dermatol, 2020,83（1）:71⁃77. doi: 10. 1016/j.jaad.2020.01.006.
［25］	Navarro R, Villar⁃Zarra K, Juarez Á, et al. Histopathologic study of paradoxical psoriasis induced by antitumor necrosis factor alpha therapy: is it true psoriasis?［J］. J Cutan Pathol, 2021,48（6）:813⁃816. doi: 10.1111/cup.13919.
［26］	Benzaquen M, Flachaire B, Rouby F, et al. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn′s disease⁃associated spondyloarthropathy［J］. Rheumatol Int, 2018,38（7）:1297⁃1299. doi: 10.1007/s00296⁃018⁃4034⁃0.
［27］	Noell C, McQuade B, Gottlieb A, et al. Anti IL⁃17 flared psoriasis in a patient on secukinumab［J/OL］. Dermatol Ther, 2017,30（4）:e12505. doi: 10.1111/dth.12505.
［28］	Tadiotto Cicogna G, Messina F, Nalotto L, et al. Case report: paradoxical acrodermatitis of Hallopeau⁃like eruption following anti⁃IL⁃17 therapy［J］. F1000Res, 2019,8:336. doi: 10.12688/f1000research.18493.1.
［29］	Dogra S, Bishnoi A, Narang T, et al. Secukinumab⁃induced paradoxical pustular psoriasis［J］. Clin Exp Dermatol, 2019,44（1）:72⁃73. doi: 10.1111/ced.13731.
［30］	Hoshina D, Haga N, Furuya K, et al. Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab［J］. Clin Exp Dermatol, 2018,43（6）:718⁃719. doi: 10.1111/ced. 13375.
［31］	Napolitano M, Caiazzo G, Fabbrocini G, et al. Increased expression of interleukin⁃23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment［J］. Br J Dermatol, 2021,184（2）:341⁃343. doi: 10. 1111/bjd.19459.
［32］	Mirza FN, Wang A, Ramachandran SM, et al. Dupilumab⁃induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin⁃17A expression: a case report［J］. Br J Dermatol, 2021,185（2）:432⁃434. doi: 10.1111/bjd.20064.
［33］	Hayakawa M, Izumi K, Higashida⁃Konishi M, et al. Tocilizumab⁃induced psoriasis⁃like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case⁃based review［J］. Rheumatol Int, 2019,39（1）:161⁃166. doi: 10.1007/s00296⁃018⁃4175⁃1.
［34］	Matsushima Y, Hayashi A, Mizutani K, et al. Psoriasiform dermatitis developing during treatment of juvenile idiopathic arthritis with tocilizumab［J］. Case Rep Dermatol, 2019,11（3）:317⁃321. doi: 10.1159/000504429.
［35］	Zheng J, Gao Y, Ding Y. Successful management of infliximab⁃induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis［J/OL］. Dermatol Ther, 2019,32（6）:e13132. doi: 10.1111/dth.13132.
［36］	Bruzzese V, Pepe J. Efficacy of cyclosporine in the treatment of a case of infliximab⁃induced erythrodermic psoriasis［J］. Int J Immunopathol Pharmacol, 2009,22（1）:235⁃238. doi: 10.1177/039463200902200126.
［37］	Mazloom SE, Yan D, Hu JZ, et al. TNF⁃α inhibitor⁃induced psoriasis: a decade of experience at the Cleveland Clinic［J］. J Am Acad Dermatol, 2020,83（6）:1590⁃1598. doi: 10.1016/j.jaad. 2018.12.018.
［38］	Koumaki D, Koumaki V, Katoulis A, et al. Adalimumab⁃induced scalp psoriasis with severe alopecia as a paradoxical effect in a patient with Crohn′s disease successfully treated with ustekinumab［J/OL］. Dermatol Ther, 2020,33（4）:e13791. doi: 10.1111/dth.13791.
［39］	Bonomo L, de Moll EH, Li L, et al. Tumor necrosis factor inhibitor⁃induced psoriasis in a pediatric Crohn′s disease patient successfully treated with ustekinumab［J］. J Drugs Dermatol, 2020,19（3）:328⁃331.
［40］	Li SJ, Perez⁃Chada LM, Merola JF. TNF inhibitor⁃induced psoriasis: proposed algorithm for treatment and management［J］. J Psoriasis Psoriatic Arthritis, 2019,4（2）:70⁃80. doi: 10.1177/2475530318810851.

[1]	丁瑞张卫亮李静陈羽佳李珺莹. 度普利尤单抗治疗5例难治性内源性角化型手足部湿疹[J]. 中华皮肤科杂志, 2024, 0(4): 20230429-e20230429.
[2]	陈星宇姚煦. 中性粒细胞在炎症性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220865-e20220865.
[3]	吴玉冰王晓宇安彬祎吴莹莹桑红孔庆涛. 环鸟苷酸-腺苷酸合成酶-干扰素基因刺激因子信号通路在银屑病发病中的作用[J]. 中华皮肤科杂志, 2024, 0(3): 20230394-e20230394.
[4]	朱婷婷张学军. 阿普米司特在斑块状银屑病治疗中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230448-e20230448.
[5]	郝丹王怡怡肖月闫薇李薇. [开放获取] 特殊部位银屑病系统治疗临床研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230190-e20230190.
[6]	宗杨永怡马楚君苏忠兰. 银屑病生物制剂治疗后湿疹化发生机制及应对策略[J]. 中华皮肤科杂志, 2024, 0(3): 20220578-e20220578.
[7]	王煜坤刘洁. 深度学习在非肿瘤性皮肤病中的应用进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220660-e20220660.
[8]	姚我汪慧英. [开放获取] 拉那利尤单抗治疗遗传性血管性水肿临床试验的系统综述[J]. 中华皮肤科杂志, 2024, 0(3): 20230378-e20230378.
[9]	中国医师协会皮肤科医师分会中华医学会皮肤性病学分会中国医疗保健国际交流促进会皮肤医学分会疑难重症及罕见病国家重点实验室国家皮肤与免疫疾病临床医学研究中心. 特应性皮炎治疗药物应用管理专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(2): 97-108.
[10]	王诗琪王爱平李航李若瑜. 趾甲银屑病与指甲银屑病的皮肤镜特征比较[J]. 中华皮肤科杂志, 2024, 57(2): 161-165.
[11]	刘小扬赵琰蔡林张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848.
[12]	付丹丹李佳林付修宇张芯育胡华宋向凤田中伟. S100A10蛋白在银屑病皮损的表达及对小鼠银屑病样皮炎模型的影响[J]. 中华皮肤科杂志, 2023, 56(9): 839-844.
[13]	宋志强陈奇权葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723.
[14]	周彤耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793.
[15]	陈小敏张景展丁媛康晓静. 二甲双胍治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(8): 799-802.

肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床进展

Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 40

相关文章 15

Metrics

本文评价

推荐阅读 10